This research page is under internal review and has not been approved for publication. Content and figures may still change.
Retatrutide
Retatrutide (development code LY3437943) is an investigational peptide studied as a single molecule that acts on three receptors at once: GIP, GLP-1 and glucagon. It is one of the more closely watched compounds in metabolic research. It is not approved for human use by the EMA or the FDA.
In short
A synthetic peptide analogue with a fatty-acid modification that extends its half-life. The exact sequence and molecular weight are listed on each batch's certificate of analysis rather than stated in marketing copy.
How it is studied
In published research, retatrutide acts as an agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. Combining all three targets in one molecule is what separates it from single- and dual-agonist peptides.
Research status
Investigational. Phase 2 trials in obesity and in type 2 diabetes have been published, and a phase 3 programme is ongoing. No regulator has approved retatrutide for any indication. The published results describe the compound as studied under clinical protocols and dosing. They say nothing about the ARDEN ONE research format, which is not a medicine and not for human use.
Literature
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial. New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2301972
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet, 2023. doi:10.1016/S0140-6736(23)01053-X
Batch and certificate of analysis
The ARDEN ONE retatrutide format has no signed batch record published yet. Batch identity, HPLC purity, method (RP-HPLC and ESI-MS), laboratory and test date will appear here and in the Batch Library once a production run is analysed. Until then this product is marked verification pending.
Handling and storage
Supplied as a lyophilised powder in a research-pen format. Store cool and dry, away from light. Reconstitution and handling follow standard laboratory practice.
What we do not claim
ARDEN ONE makes no medical, therapeutic or performance claims about retatrutide. We do not state that it treats, prevents or improves any condition. It is supplied for laboratory research use only, not for human or animal consumption. The literature above concerns the compound as studied in controlled trials and is provided for scientific context, not as a claim about this product.
Questions
- Is retatrutide approved for use?
- No. It is an investigational compound. No regulator has approved it, and ARDEN ONE supplies it for laboratory research only.
- What receptors does retatrutide target?
- In published research it acts as an agonist at the GIP, GLP-1 and glucagon receptors.
- Does the ARDEN ONE format come with a certificate of analysis?
- Each production batch is intended to carry an independent certificate of analysis, resolvable by its batch code. This product is marked verification pending until that record is signed and published.